Revalesio
Biotechnology ResearchWashington, United States11-50 Employees
Revalesio is a clinical-stage biotechnology company focused on developing therapies for neurological diseases with limited treatment options. Its approach targets cellular imbalances arising from mitochondrial dysfunction to modulate immune responses. In preclinical models, its candidates have shown neuronal protection in chronic neurological disease contexts and improved recovery after acute neurological injury. The company works with renowned researchers in biomedical science to advance its research program. Based in Tacoma, Washington, Revalesio positions itself as a small to mid-sized enterprise within the biotechnology research sector. In 2025, it shared post-hoc analyses from the Phase 2 RESCUE trial of its investigational drug, RNS60, at major stroke-focused conferences, signaling ongoing clinical exploration of its neuroprotective program.
1-888-653-2347 
support@leadiq.com 
